Winship Cancer Institute

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Retrieved on: 
Friday, March 15, 2024
Biotechnology, FDA, Pharmaceutical, Health, Emory University, Multiple myeloma, BMY, Development, Survival, ASH, Disease, Oncology, Patient, FACP, Committee, EMA, Cell therapy, Bristol Myers Squibb, MD, Winship Cancer Institute, European Medicines Agency, Society, ODAC, CHMP, Food, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.
  • The recommendation from the ODAC will be considered by the FDA during its ongoing review of the supplemental Biologics License Application (sBLA) for Abecma for this patient population.
  • The FDA has not yet assigned a new target action date for review of the sBLA.
  • “With patients becoming triple-class exposed earlier in the multiple myeloma treatment paradigm, it is critical that new treatment options with the potential to improve long-term outcomes are available as early as possible,” said Sagar Lonial, MD, FACP, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University.

Manifold Secures $15 Million in Investment and Launches AI-Powered Platform to Accelerate Clinical Research

Retrieved on: 
Thursday, April 4, 2024
Emory University, Organization, Entrepreneurship, Partner (business rank), Partnership, Foundation Medicine, Patient, SVP, Research, Robotics, Electronic health record, MD, Winship Cancer Institute, Data management

NEWTON, Mass., April 4, 2024 /PRNewswire/ -- Manifold, an AI-powered clinical research platform, today announced a $15 million Series A. Led by TQ Ventures, the funding round also includes new investors Calibrate Ventures and SK Ventures, notable founders and CEOs including healthcare leader Dr. Sachin H. Jain and existing investors including TTCER Partners. Built by industry veterans, Manifold's platform streamlines the manual workflows of modern study and data management. Manifold has already helped research teams reduce the time to insights from months to minutes — a critical metric of research productivity.

Key Points: 
  • NEWTON, Mass., April 4, 2024 /PRNewswire/ -- Manifold , an AI-powered clinical research platform, today announced a $15 million Series A.
  • Manifold has already helped research teams reduce the time to insights from months to minutes — a critical metric of research productivity.
  • Manifold's AI-powered platform dramatically accelerates modern research studies, enabling researchers to rapidly collect, curate, and analyze comprehensive patient data.
  • "Manifold is transforming clinical research by providing research organizations with purpose-built technology infrastructure for this new era," said Vinay Seth Mohta, CEO and Co-Founder of Manifold.

Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade

Retrieved on: 
Thursday, March 28, 2024
Emory University, CD4, CD8, Immunotherapy, Lab, Oncology, Inflammation, Patient, Immunosuppression, Neoplasm, Research, ATX, Cancer, Lung cancer, Winship Cancer Institute, Fibrosis, Hematology, Pharmaceutical industry

As a member of the cancer immunology research program at Winship Cancer Institute of Emory University, Dr. Konen's research has shown that autotaxin has a direct impact on the body's immune response to tumors.

Key Points: 
  • As a member of the cancer immunology research program at Winship Cancer Institute of Emory University, Dr. Konen's research has shown that autotaxin has a direct impact on the body's immune response to tumors.
  • The ongoing research collaboration is dedicated to investigating the potential benefits of combining BBT-877 with anti-PD-1 therapy as a treatment approach.
  • "We are pleased to work with Bridge Biotherapeutics to explore indication expansion into NSCLC through a combination of BBT-877 with anti-PD-1 agent and potentially offer new hope to those patients."
  • Together, the two entities will conduct preclinical studies to evaluate the therapeutic potential of BBT-877 in enhancing anti-tumor immunity.

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Retrieved on: 
Monday, February 19, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NSCLC, Fever, Progression-free survival, PFS, AstraZeneca, Heart, Periodic breathing, QT interval, MD, Chemoradiotherapy, Cough, Pemetrexed, Winship Cancer Institute, QT, OS, Electrolyte, Cardiomyopathy, Lung cancer, Safety, Emory University, CRT, LAURA, ILD, Patient, LVEF, Brain, Pharmaceutical industry

In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.

Key Points: 
  • In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 TAGRISSO-treated patients; 0.4% of cases were fatal.
  • TAGRISSO is the only targeted therapy to improve patient outcomes in both early-stage disease in the ADAURA Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2 Phase III trial .
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

City of Hope appoints Kristin Higgins, M.D., as chief clinical officer at City of Hope Cancer Center Atlanta

Retrieved on: 
Tuesday, January 23, 2024
Biotechnology, Health, General Health, Radiology, Pharmaceutical, Oncology, Research, Hospitals, Genetics, Science, Clinical Trials, Winship Cancer Institute, Patient, Radiation, City, Multimedia, Carcinoma, Discovery, Cancer, Lung cancer, Quality of life, National Cancer Institute, Emory Healthcare, Pharmaceutical industry

City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Kristin Higgins , M.D., as the chief clinical officer at City of Hope Cancer Center Atlanta.

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Kristin Higgins , M.D., as the chief clinical officer at City of Hope Cancer Center Atlanta.
  • View the full release here: https://www.businesswire.com/news/home/20240123399682/en/
    Kristin Higgins, M.D., chief clinical officer, City of Hope Cancer Center Atlanta.
  • (Photo: City of Hope)
    Higgins will act as senior clinical leader for City of Hope Cancer Center Atlanta, responsible for overall clinical care decisions and cancer care innovation.
  • “We are thrilled to welcome Dr. Higgins to City of Hope Cancer Center Atlanta.

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

Retrieved on: 
Tuesday, January 9, 2024
KICKSTART, Winship Cancer Institute, Patient, Therapy, Hematology, Cancer, Q&A, NSCLC, ZFA, Pembrolizumab, Effector, Oncology, Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.

Key Points: 
  • -  Webinar to take place on Wednesday, January 24, 2024, at 4:30 pm ET-
    SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.
  • The eFFECTOR Investor R&D Day will feature the management team and include a presentation by Kevin Kalinsky, MD, MS, professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of the Glenn Family Breast Center at the Winship Cancer Institute.
  • Steve Worland, Ph.D., president and chief executive officer of eFFECTOR said: “We are pleased with the development progress of both of our wholly-owned Phase 2 drug candidates.
  • We look forward to showcasing both of our tomivosertib and zotatifin programs at our Investor R&D Day and are excited to have Dr. Kalinsky share his insights.”
    The presentations will be followed by a live Q&A session.

Bio Ascend, a Vaniam Group Company, Reconvenes Inaugural Class of the "Academy of Next Wave of Investigators™" in CLL and NHL

Retrieved on: 
Monday, December 11, 2023
Leukemia Research, Associate, Research, Associate professor, SAN, Senior, Non-Hodgkin lymphoma, Weill Cornell Medicine, ASH, Leukemia, Emory University, Dana–Farber Cancer Institute, Clinical research, Chairperson, Patient, Faculty, Indolent lymphoma, Division, Mentorship, Chronic lymphocytic leukemia, University, Winship Cancer Institute, Oncology, Columbia University, US-China strategic engagement, MMSc, Society, NHL, MD Anderson Cancer Center, Innovation, CLL, Health, Next wave, Management, Hospital, Hematology, MD, Lymphoma

SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Bio Ascend, Vaniam Group's medical education company, this past weekend reconvened the inaugural class of its Academy of Next Wave of Investigators™ at a networking reception during the 65th annual American Society of Hematology (ASH) annual meeting. These young clinical investigators are participating in a year-long opportunity to engage in live and virtual career development seminars with international thought leaders in the fields of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Key Points: 
  • These young clinical investigators are participating in a year-long opportunity to engage in live and virtual career development seminars with international thought leaders in the fields of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
  • "This next generation of hematology leaders is at a critical moment in their promising careers," said Kraig Steubing, Head of Bio Ascend and Senior Vice President of Strategic Engagement at Vaniam Group.
  • We wholeheartedly thank the members of our inaugural class, our distinguished faculty, and the program's sponsors."
  • In the subsequent months, the early-career investigators have been meeting regularly with their assigned mentors, prior to reconvening in person at the ASH annual meeting this past weekend.

LUNGevity Foundation's No One Missed Campaign Commemorates Third Year of #KnowYourBiomarker Storytelling Initiative

Retrieved on: 
Wednesday, November 1, 2023
Aurora, Insurance, NSCLC, Cancer Support Community, Lung cancer, Wellstar Health System, Organization, Hope, Northside Hospital, ALK, Research, Progress, Chest pain, Disease, Winship Cancer Institute, NED, Radiation, Emory University, Biopsy, CT, X-ray, Immunotherapy, Personalized medicine, Fertility preservation, Cancer, Patient, Diagnosis, Prognosis, Mutation, EGFR, Medical imaging, Atlanta

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit, today celebrates the third year of #KnowYourBiomarker, a social media initiative that highlights the stories of people living well with lung cancer. The initiative is part of LUNGevity's No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Key Points: 
  • She started chemotherapy, which resulted in awful side effects that prevented her from being able to work.
  • After her healthcare team ordered biomarker testing, they discovered her cancer was positive for the ALK mutation and matched Shirley with a targeted therapy.
  • Now, three years after her diagnosis, Shirley is living her life to the fullest.
  • In addition to No One Missed's #KnowYourBiomarker initiative, LUNGevity has other ways to get involved during Lung Cancer Awareness Month.

AccessHope Announces Foundational Partnership with Johns Hopkins Medicine to Expand Cancer Expertise Access in Mid-Atlantic Region

Retrieved on: 
Tuesday, September 19, 2023
Emory University, Partnership, City of Hope, Travel, Winship Cancer Institute, Teaching, Survival, NCI-designated Cancer Center, Cancer, Toxicity, Research, National Cancer Institute, Johns Hopkins School of Medicine, City, Patient, Physician, Emory Healthcare, Johns Hopkins Medicine International, Johns Hopkins, Fred Hutchinson Cancer Research Center, Geography, Health, NCI, Complex, Dana–Farber Cancer Institute, Pharmaceutical industry, Northwestern Medicine

"Complex cancer cases often require expertise from subspecialists that are limited to leading academic centers, but many people cannot reasonably travel to these facilities.

Key Points: 
  • "Complex cancer cases often require expertise from subspecialists that are limited to leading academic centers, but many people cannot reasonably travel to these facilities.
  • Collaborating with Johns Hopkins Medicine's Sidney Kimmel Comprehensive Cancer Center will greatly extend our reach and ability to help more people with complex cancer cases access world-renowned expertise that can improve their care journey."
  • The Kimmel Cancer Center is the sixth collaboration between AccessHope and a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, with other foundational partners including City of Hope, Dana-Farber Cancer Institute, Emory Healthcare and Winship Cancer Institute of Emory University, Fred Hutchinson Cancer Center, and Northwestern Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • With AccessHope, Johns Hopkins intends to bring this expertise to more patients in the mid-Atlantic region.

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

Retrieved on: 
Friday, September 8, 2023
Health, Science, Research, Clinical Trials, Oncology, WCLC, Emory University, MDT, Emory University School of Medicine, ICI, Winship Cancer Institute, Hematology, Survival, Convention, OS, Case report, Lung cancer, International Association, NSCLC, TPS, National Primate Research Exhibition Hall, Patient, PD-L1, Conference, Pharmaceutical industry, Medical imaging, Hospital, Medicine

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore.
  • Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer, including a new post-hoc analysis of data from its LUNAR trial in metastatic non-small cell lung cancer.
  • The LUNAR trial was designed to evaluate the use of TTFields therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer, following progression on or after platinum-based therapy.
  • “This analysis further elucidates the promising results from the LUNAR trial and the potential benefit of utilizing TTFields therapy for the treatment of metastatic non-small cell lung cancer,” Dr. Leal said.